Blog
Blog
The CI Capacity Squeeze, and Three Questions To Ask Before 2027 Planning
Every year the competitive field gets more crowded: more assets, more readouts, more congress abstracts, more competitor moves to track. Products are more complex too, from special distribution to patient and healthcare professional (HCP) education requirements. And every year, pharma competitive intelligence (CI) teams are asked to cover more of it. What’s changed is that resources aren’t keeping up.
Filter posts by:
Blog
Catalysts of Change: Four Innovations Redefining Interventional Cardiology
Interventional cardiology continues to advance toward precision-based care, where treatment strategies are matched to patient characteristics and real-world outcomes guide decision-making. Coming out of TCT 2025, one of the leading interventional cardiology conferences, Trinity sees four trends shaping the next 2-3...
Blog
U.S. MFN Drug Pricing: What 2025’s Executive Order Means for Global Pharma
The Most Favored Nation (MFN) pricing policy is once again under consideration in the U.S. First put forward in a 2020 Executive Order (EO) by the Trump Administration, the 2025 MFN policy aims to eliminate global free riding by aligning United...
Blog
AI-driven Advancements in Life Sciences
The momentum behind AI-driven advancements in life sciences has never been stronger, and this trend was spotlighted in Everest Group’s new 2025 PEAK Matrix® report, “Life Sciences AI and Analytics Services for Commercial PEAK Matrix® Assessment 2025.” Trinity Life Sciences is...
Blog
A Shrinking Safety Net: OBBBA’s Ripple Effects on the Pharma Industry
President Trump signed the “One Big Beautiful Bill Act” (OBBBA) into law on July 4, 2025. The OBBBA is projected to reduce federal health spending by an estimated $900 billion[1] over the next decade. Central to the legislation is the estimated...
Blog
Trinity Life Sciences Unveils Groundbreaking Trinity Digital Affinity, Powered by DeepIntent, to Transform HCP Engagement for Life Sciences
In today’s fast-evolving digital landscape, life sciences companies face a critical challenge: reach the right healthcare professionals (HCPs) with the right message, through the right channels, at the right time. At Trinity Life Sciences, we’re proud to help our clients meet...
Blog
NRDL 2024: Rare Diseases Deep Dive
China’s pharmaceutical landscape is not only vast in scale but also rapidly evolving with an emphasis on balancing access with affordability. This year’s NRDL update stands out. The introduction of the value rating system continues to raise the bar for clinical...
